A study of onabotulinum toxin type A for the treatment of ultraviolet B-induced hyperpigmentation: a prospective, randomized, controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211111002

Enrollment

Registered

2021-11-11

Start date

2021-08-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

UVB-induced hyperpigmentation UVB, hyperpigmentation, onabotulinum toxin

Interventions

No treatment,injected with normal saline once,injected with this dose once,injected with this dose once,injected with this dose once

No Intervention No treatment,Placebo Comparator Drug,Experimental Drug,Experimental Drug,Experimental Drug

No treatment,Normal saline,OnabotulinumtoxinA 1:2.5 concentration,OnabotulinumtoxinA 1:5 concentration,OnabotulinumtoxinA 1:7.5 concentration

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy subjects older than 18-year-old

Exclusion criteria

Exclusion criteria: the subjects who have the serious underlying diseases, pregnancy, active skin diseases, allergic reaction to BoNT-A, history of photosensitive disorders, and ongoing use of topical medications or laser procedures at the experimental sites

Design outcomes

Primary

Measure	Time frame
mean lightness index 0, 7, 21, 28, 35-week colorimeter	—

Secondary

Measure	Time frame
improvement score 35-week blinded physician	—

Countries

Thailand

Contacts

Public ContactVasanop Vachiramon

Faculty of Medicine, Ramathibodi hospital

vasanop@gmail.com0946369165

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026